DK178513B1 - Insecticide combination preparation for use against mammalian blood mites, especially cats and dogs - Google Patents
Insecticide combination preparation for use against mammalian blood mites, especially cats and dogs Download PDFInfo
- Publication number
- DK178513B1 DK178513B1 DKPA201370137A DKPA201370137A DK178513B1 DK 178513 B1 DK178513 B1 DK 178513B1 DK PA201370137 A DKPA201370137 A DK PA201370137A DK PA201370137 A DKPA201370137 A DK PA201370137A DK 178513 B1 DK178513 B1 DK 178513B1
- Authority
- DK
- Denmark
- Prior art keywords
- composition
- use according
- compound
- solvent
- preparation
- Prior art date
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Fremgangsmade og præparat især til bekæmpelse af blodmider på små pattedyr karakteriseret ved, at præparatet pa den ene side omfatter mindst et insekticid af 1-N-arylpyrazoltypen, især fipronil, og pa den anden side mindst en forbindelse af den insektvækstregulerende (IGR) type i doser og forhold, som er parasiticidt effektive mod blodmider, i en flydende vehikel, som er acceptabel for dyret og bekvemt til lokal anbringelse på huden, fortrinsvis lokaliseret til et lille overfladeareal.A method and composition in particular for controlling blood mites on small mammals characterized in that the composition comprises on the one hand at least one insecticide of the 1-N-arylpyrazole type, especially fipronil, and on the other hand at least one compound of the insect growth regulating (IGR) type. doses and ratios that are parasitically effective against blood mites in a liquid vehicle acceptable to the animal and convenient for local application to the skin, preferably located to a small surface area.
Description
Den foreliggende opfindelse angår et præparat til anvendelse for langvarig beskyttelse mod blodmider på små pattedyr og især blodmider på katte og hunde. Opfindelsen angår et hidtil ukendt præparat til denne anvendelse, hvilket præparat er baseret på den synergistiske kombination af parasiticider, der allerede er kendte.The present invention relates to a composition for use in long-term protection against anemia in small mammals and in particular anemia in cats and dogs. The invention relates to a novel composition for this use, which is based on the synergistic combination of parasiticides already known.
En hidtil ukendt klasse 1-N-arylpyrazol-baserede insekticider er blevet beskrevet i EP patentskrift A-295.217 og A-352.944. Forbindelserne af de i disse patenter definerede klasser er yderst aktive, og én af disse forbindelser 1- [2,6-Cl2-4-CF3-phenyl] -3-CN-4- [SO-CF3] -5-NH2-pyrazol, hvis almindelige navn er fipronil, har vist sig at være særlig effektiv mod ikke blot parasitter på afgrøder, men også mod ectoparasitter på pattedyr og især, men ikke udelukkende, lopper, blodmider, fluer og myiaser.A novel class 1-N-arylpyrazole-based insecticide has been disclosed in EP Patent A-295,217 and A-352,944. The compounds of the classes defined in these patents are highly active, and one of these compounds 1- [2,6-Cl2-4-CF3-phenyl] -3-CN-4- [SO-CF3] -5-NH2-pyrazole , whose common name is fipronil, has been found to be particularly effective against not only crop parasites but also against mammalian ectoparasites and in particular, but not exclusively, fleas, mites, flies and myiasis.
Forbindelser med en ovicid og/eller larvicid virkning på de umodne stadier af forskellige ectoparasitter er allerede kendt fra f.eks. US patentskrift A-5.439.924. Blandt disse forbindelser optræder insektvækstregulatoriske (IGR) forbindelser, som enten virker ved blokering af udviklingen af de umodne trin (æg og larver) til voksenstadier eller ved in-hibering af syntesen af chitin.Compounds having an ovicidal and / or larvicidal effect on the immature stages of various ectoparasites are already known from e.g. U.S. Patent A-5,439,924. Among these compounds are insect growth regulatory (IGR) compounds which act either by blocking the development of the immature stages (eggs and larvae) to adult stages or by inhibiting the synthesis of chitin.
Endvidere kendes FR patentskrift A-2.713.889, som generelt beskriver kombinationen af mindst én forbindelse af den insektvækstregulatoriske (IGR) type omfattende forbindelser med juvenilhormon-aktivitet og chitinsynteseinhibitorer med mindst én blandt tre N-aryldiazolforbindelser, især fipronil, til bekæmpelse af mange skadelige insekter, der tilhører meget varierede ordener.Furthermore, FR patent specification A-2,713,889, which generally describes the combination of at least one compound of the insect growth regulatory (IGR) type comprising compounds with juvenile hormone activity and chitin synthesis inhibitors with at least one of three N-aryldiazole compounds, especially fipronil, is known to combat many harmful insects belonging to highly varied orders.
Præparaterne kan benyttes på meget forskellige former, uden at det hverken er præciseret til hvilke anvendelser, f.eks. veterinære, sundhedsmæssige eller plantebeskyttende, disse forskellige former er bestemt, eller til hvilke parasitter, hvortil de henholdsvis er bestemt.The compositions can be used in very different forms, without specifying what uses, e.g. veterinary, health or plant protection, these various forms are determined or to which parasites to which they are designated respectively.
Den eneste anvendelse, som kan tænkes at være veterinær, er forbundet med eksemplet på fremstilling af et pesticidhalsbånd, som er en formulering med langsom frigivelse.The only use which is likely to be veterinary is associated with the example of the preparation of a pesticide collar which is a slow release formulation.
Ifølge opfindelsen foreslås en forbedring af bekæmpelse af blodmider hos små pattedyr og især hos katte og hunde.According to the invention, an improvement in the control of blood mites is proposed in small mammals and especially in cats and dogs.
Opfindelsen har især til formål at anvende allerede kendte parasiticider til fremstilling af et præparat, som er yderst aktiv mod disse dyrs blodmider.In particular, the invention aims to use already known parasiticides to produce a composition which is highly active against the blood mites of these animals.
Endelig har opfindelsen til formål at tilvejebringe et hidtil ukendt præparat, der således er fremstillet og især bestemt til bekæmpelse af blodmider.Finally, the object of the invention is to provide a novel composition thus prepared and particularly intended for the control of blood mites.
Den meget høje effektivitet af præparatet ifølge opfindelsen indebærer ikke kun høj umiddelbar effektivitet, men også meget langvarig effektivitet, efter at dyret er blevet behandlet.The very high efficiency of the composition according to the invention implies not only high immediate efficiency but also very long-lasting efficiency after the animal has been treated.
Opfindelsen har til formål at kunne anvendes i en fremgangsmåde til bekæmpelse af blodmider hos små pattedyr og især hos katte og hunde i et langt tidsrum, hvilken fremgangsmåde er ejendommelig ved, at dyret behandles ved lokalt på huden, fortrinsvis lokaliseret til et lille overfladeareal (spot-on-administra-tion), i parasiticidt effektive doser og forhold at anbringe på den ene side mindst én forbindelse (A) 1-[2,6-CL2-4-CF3-phenyl]-3-CN-4-[SO-CFs]-5-NH2-pyrazol og på den anden side, mindst én ovicid forbindelse (B) af den insektvækstregulatoriske (IGR) type der efterligner juvenile hormoner valgt blandt hydroprene, methoprene og pyriproxyfene, i en flydende vehikel, der er acceptabelt for dyret og er egnet til lokal eller punktvis administration på huden, hvor præparatet omfatter 5-15% (vægt/volumen) 1-[2,6-CI2-4-CF3-phenyl]-3-CN-4-[SO-CF3]-5-NH2-pyrazol og 1-20% (vægt (volumen) af forbindelse (B) , og hvor den flydende vehikel og koncentrationen af forbindelserne (A) og (B) er indrettet til punktuel tilføring af typen "spot-on" ved anbringelse på huden og hvor præparatet omfatter et organisk opløsningsmiddel (c) med en dielektrisk konstant på mellem 10 og 35, hvor dette organiske opløsningsmiddel (c) er valgt blandt acetone, acetonitril, benzylalkohol, butyldiglycol, dimethylacet-amid, dimethylformamid, dipropylenglycol-n-butylether, ethanol, isopropanol, methanol, ethylenglycol-monoethylether, ethylen-glycol-monomethylether, monomethylacet-amid, dipropylengiycol-monomethylether, flydende polyoxyethylenglycoler, propylenglycol, 2-pyrrolidon, N-methylpyrrolidon, diethylenglycol-monoethylether, ethy-lenglycol, diethylphthalat, eller en blanding af mindst to af disse opløsninger.The invention has for its object to be applicable in a method for controlling blood mites in small mammals and especially in cats and dogs for a long period of time, which is characterized in that the animal is treated locally on the skin, preferably located to a small surface area (spot -on administration) to apply at least one compound (A) 1- [2,6-CL2-4-CF3-phenyl] -3-CN-4- [SO -CFs] -5-NH 2 -pyrazole and, on the other hand, at least one ovicidal compound (B) of the insect growth regulatory (IGR) type that mimics juvenile hormones selected from the hydrogens, methoprene and pyriproxyfen, in a liquid vehicle acceptable for the animal and is suitable for topical or spot administration to the skin, wherein the composition comprises 5-15% (w / v) 1- [2,6-Cl 2 -4-CF3-phenyl] -3-CN-4- [SO-CF3 ] -5-NH 2 -pyrazole and 1-20% (weight (volume) of compound (B) and where the liquid vehicle and concentration of compounds (A ) and (B) are adapted for spot-on type spot-on application on the skin and wherein the composition comprises an organic solvent (c) having a dielectric constant of between 10 and 35, wherein said organic solvent (c) is selected. among acetone, acetonitrile, benzyl alcohol, butyldiglycol, dimethylacetamide, dimethylformamide, dipropylene glycol-n-butyl ether, ethanol, isopropanol, methanol, ethylene glycol monoethyl ether, ethylene glycol monomethyl ether, monomethyl acetylene ethylene, dipropylene glycol, dipropylene glycol 2-pyrrolidone, N-methylpyrrolidone, diethylene glycol monoethyl ether, ethylene glycol, diethyl phthalate, or a mixture of at least two of these solutions.
Forbindelserne (B) af den insektvækstregulatoriske (IGR) type som imiterer juvenilhormoner er: hydroprene (Sandoz) methoprene (Sandoz) pyriproxyfene (Sumitomo/Mgk) idet disse forbindelser er defineret ved deres internationale, almindelige navn (The Pesticice Manual, 10. udgave, 1994, redaktør Clive Tomlin, Storbritannien).The compounds (B) of the insect growth regulatory (IGR) type that mimic juvenile hormones are: hydroprene (Sandoz) methoprene (Sandoz) pyriproxyfene (Sumitomo / Mgk) as these compounds are defined by their international, common name (The Pesticice Manual, 10th edition, 1994, editor Clive Tomlin, UK).
Det foretrækkes, at administrationen af de to typer forbindelser sker jævnsides og fortrinsvis fælles.It is preferred that the administration of the two types of compounds be parallel and preferably joint.
Det foretrækkes, at behandlingen udføres hver anden eller fortrinsvis hver tredje måned på katte og hunde.It is preferred that the treatment be performed every second or preferably every three months on cats and dogs.
Fortrinsvis udføres behandlingen således, at der til dyret administreres en dosis på 0,1 til 40 og især på 1 til 20 mg/kg med hensyn til derivat (A) og en dosis på 0,1 til 40 og især 1 til 30 mg/kg med hensyn til forbindelse (B).Preferably, the treatment is carried out such that a dose of 0.1 to 40 and in particular of 1 to 20 mg / kg for derivative (A) and a dose of 0.1 to 40 and in particular 1 to 30 mg / kg is administered to the animal. kg of compound (B).
De foretrukne doser er fra 5 til 15 mg/kg med hensyn til forbindelse (A) og fra 0,5 til 15 mg/kg med hensyn til de foretrukne forbindelser (B), eller 10 til 20 mg/kg med hensyn til de andre forbindelser (B).The preferred dosages are from 5 to 15 mg / kg with respect to compound (A) and from 0.5 to 15 mg / kg with respect to preferred compounds (B), or from 10 to 20 mg / kg with respect to the other compounds. compounds (B).
Ved en anden udførelsesform af fremgangsmåden kan forbindelse (A) og (B) administreres på en tidsmæssigt adskilt og opdelt måde. I dette tilfælde foretrækkes det at lade administrationerne veksle med et interval på f.eks. 1 måned mellem to administreringer, idet den første administrering fortrinsvis foretages med forbindelsen (A).In another embodiment of the method, compounds (A) and (B) can be administered in a temporally separated and divided manner. In this case, it is preferred to allow the administrations to alternate with an interval of e.g. 1 month between two administrations, the first administration being preferably done with compound (A).
Det vil være åbenbart, at dosisværdierne, som således er angivet, er gennemsnitsværdier, som kan variere inden for et bredt interval, da i praksis en formulering med nærmere angivne doser af forbindelse (A) af derivatet af 1-N-phenylpyrazol-typen og af forbindelse (B) vil blive administreret til dyr med forholdsvis afvigende vægte. Som følge heraf er de faktisk administrerede doser ofte mindre eller større med en faktor, som kan være op til 2, 3 eller 4 i forhold til den foretrukne dosis uden at medføre nogen toksisk risiko for dyret i tilfælde af en overdosis, og medens der samtidig bibeholdes en virkelig effektivitet af mulig mindre varighed i tilfælde af en underdosis.It will be apparent that the dose values thus indicated are average values which may vary over a wide range, since in practice a formulation with specified doses of compound (A) of the derivative of the 1-N-phenylpyrazole type and of compound (B) will be administered to animals of comparatively different weights. As a result, the doses actually administered are often smaller or larger by a factor that may be up to 2, 3 or 4 relative to the preferred dose without causing any toxic risk to the animal in the event of an overdose, while at the same time. a true efficiency of possible lesser duration is maintained in the case of a sub-dose.
Formålet med denne fremgangsmåde er ikke-terapeutisk og vedrører især rensning af dyrets hår og hud ved eliminering af parasitterne, som er til stede såvel som deres rester og ekskrementer. De behandlede dyr har således hår, der er mere behageligt at se på og røre ved.The purpose of this method is non-therapeutic and particularly concerns the purification of the animal's hair and skin by eliminating the parasites present as well as their remnants and excrement. Thus, the treated animals have hair that is more comfortable to look at and touch.
Den ovenfor beskrevne fremgangsmåde kan også anvendes til bekæmpelse af ectoparasitter, især blodmider.The method described above can also be used to control ectoparasites, especially blood mites.
Opfindelsen har ligeledes til formål at tilvejebringe et præparat og især et præparat til anvendelse for langvarig beskyttelse mod blodmider på små pattedyr, og især hos katte og hunde, hvilket præparat er ejendommeligt ved, at det på den ene side omfatter mindst én forbindelse (A) 1-[2,6-CL2-4-CF3- phenyl ]-3-CN-4-[ SO-CF3]-5-NH2-pyrazol og på den anden side mindst én ovicid forbindelse (B) af den insekstvækstregulatoriske (IGR) type der efterligner juvenile hormoner valgt blandt hydroprene, methoprene og pyriproxyfene angivet ovenfor i doser og forhold, som har parasitisid virkning på blodmider, i et flydende vehikel, som er acceptabelt for dyret og egnet til lokal eller punktvis administration på huden, og hvor præparatet omfatter 5-15% (vægt/volumen) 1-[2,6-C12-4-CF3-phenyl ]-3-CN-4-[ SO-CF3]-5-NH2-pyrazol og 1-20% (vægt(volumen) af forbindelse (B) , og hvor den flydende vehikel og koncentrationen af forbindelserne (A) og (B) er indrettet til punktuel tilføring af typen "spot-on" ved anbringelse på huden og hvor præparatet omfatter et organisk opløsningsmiddel (c) med en dielektrisk konstant på mellem 10 og 35, hvor dette organiske opløsningsmiddel (c) er valgt blandt acetone, acetonitril, benzylalkohol, butyldiglycol, dimethylacet-amid, dimethylformamid, dipropylenglycol-n-butylether, ethanol, isopropanol, methanol, ethylenglycol-monoethylether, ethylen-glycol-monomethylether, monomethylacet-amid, dipropylengiycol-monomethylether, flydende polyoxyethylenglycoler, propylenglycol, 2-pyrrolidon, N-methylpyrrolidon, diethylenglycol-monoethylether, ethy-lenglycol, diethylphthalat, eller en blanding af mindst to af disse opløsninger.The invention also aims to provide a composition and in particular a composition for use for long-term protection against mites on small mammals, and especially in cats and dogs, characterized in that it comprises at least one compound (A). 1- [2,6-CL2-4-CF3-phenyl] -3-CN-4- [SO-CF3] -5-NH2-pyrazole and on the other hand at least one ovicidal compound (B) of the insect growth regulator (IGR) ) type which mimics juvenile hormones selected from the hydroprene, methoprene and pyriproxyphenes listed above in doses and ratios that have parasitic action on blood mites, in a liquid vehicle acceptable to the animal and suitable for topical or punctual administration to the skin, and wherein the preparation comprises 5-15% (w / v) 1- [2,6-C12-4-CF3-phenyl] -3-CN-4- [SO-CF3] -5-NH2-pyrazole and 1-20% (wt. (volume) of compound (B) and wherein the liquid vehicle and the concentration of compounds (A) and (B) are arranged for punctual delivery a f the "spot-on" type when applied to the skin and wherein the composition comprises an organic solvent (c) having a dielectric constant of between 10 and 35, wherein said organic solvent (c) is selected from acetone, acetonitrile, benzyl alcohol, butyldiglycol, dimethylacetate -amide, dimethylformamide, dipropylene glycol-n-butyl ether, ethanol, isopropanol, methanol, ethylene glycol monoethyl ether, ethylene glycol monomethyl ether, monomethylacetamide, dipropylene glycol monomethyl ether, liquid polyoxyethylene glycols, propylene glycol, N-pyrrolide glycol, 2-pyrrolide monoethyl ether, ethylene glycol, diethyl phthalate, or a mixture of at least two of these solutions.
Forbindelsen 1- [2,6-CL2-4-CF3-phenyl] -3-CN-4- [SO-CF3] -5-NH2-pyrazol kan fremstilles i overensstemmelse med en af fremgangsmåderne beskrevet i patentansøgning WO-A-87/3781, 93/6089, 94/21606 eller europæisk patentansøgning EP-A-0.295.117, eller en hvilken som helst anden fremgangsmåde der falder inden for den sagkundskab en fagmand inden for kemisk syntese besidder. Til kemisk fremstilling af produkterne ifølge opfindelsen anses fagmanden for blandt andet at have det samlede indhold af "Chemical Abstracts" og de deri citerede dokumenter til sin rådighed.The compound 1- [2,6-CL2-4-CF3-phenyl] -3-CN-4- [SO-CF3] -5-NH2-pyrazole can be prepared according to one of the methods described in patent application WO-A-87 / 3781, 93/6089, 94/21606 or European patent application EP-A-0.295.117, or any other method which falls within the expertise of a person skilled in the chemical synthesis. For the chemical preparation of the products according to the invention, the person skilled in the art is considered to have, inter alia, the complete content of "Chemical Abstracts" and the documents cited therein.
Vægtforholdene mellem forbindelse (A) 1-[2, 6-CL2-4-CF3-phenyl] -3-CN-4-[SO-CF3]-5-NH2-pyrazol og forbindelse (B) ligger fortrinsvis mellem 80/20 og 20/80.The weight ratios of compound (A) 1- [2,6-CL2-4-CF3-phenyl] -3-CN-4- [SO-CF3] -5-NH2-pyrazole and compound (B) are preferably between 80/20 and 20/80.
Det flydende vehikel kan være simpelt eller komplekst og er tilpasset den valgte administrationsvej og -måde.The liquid vehicle can be simple or complex and is adapted to the chosen route of administration and method.
Præparaterne til punktformet administration (spot-on-admini-stration) kan fordelagtigt omfatte: b) en krystallisationsinhibitor, som især er til stede i et forhold fra 1 til 20% (vægt/vol) , fortrinsvis fra 5 til 15%, idet denne inhibitor tilfredsstiller prøven i overensstemmelse hvormed: 0,3 ml af en opløsning A omfattende 10% (vægt/vol) af forbindelsen med formlen (I) i det i c) nedenfor angivne opløsningsmiddel sammen med 10% af denne inhibitor afsættes på et præparatglas ved 20°C i 24 timer, hvorefter det med det blotte øje iagttages, om der er få eller ingen krystaller, især færre end 10 krystaller og fortrinsvis 0 krystaller, på præparatglasset, c) et organisk opløsningsmiddel med en dielektrisk konstant på mellem 10 og 35, fortrinsvis mellem 20 og 30, idet indholdet af dette opløsningsmiddel c) i det totale præparat fortrinsvis udgør forskellen, der supplerer præparatet op til 100%, d) et organisk coopløsningsmiddel med et kogepunkt på under 100°C, fortrinsvis under 80°C, og med en dielektrisk konstant på mellem 10 og 40, fortrinsvis mellem 20 og 30, idet dette coopløsningsmiddel fordelagtigt kan være til stede i præparatet i et d)/c) vægt/vægt-f orhold (W/W) på mellem 1/15 og 1/2. Opløsningsmidlet er flygtigt, således at det især tjener som en tørringsfremmer og er blandbart med vand og/eller med opløsningsmiddel c).Advantages of spot-on administration (spot-on administration) may advantageously comprise: b) a crystallization inhibitor which is particularly present in a ratio of 1 to 20% (w / v), preferably from 5 to 15%, inhibitor satisfies the sample according to which: 0.3 ml of a solution A comprising 10% (w / v) of the compound of formula (I) in the ic) below, together with 10% of this inhibitor, is deposited on a slide at 20 ° C for 24 hours, after which it is observed with the naked eye whether there are few or no crystals, especially fewer than 10 crystals and preferably 0 crystals, on the preparation glass; c) an organic solvent having a dielectric constant of between 10 and 35; preferably between 20 and 30, the content of this solvent c) in the total composition preferably being the difference which supplements the composition up to 100%, d) an organic co-solvent having a boiling point below 100 ° C, preferably preferably below 80 ° C, and with a dielectric constant of between 10 and 40, preferably between 20 and 30, this co-solvent being advantageously present in the composition in a d) / c) weight / weight ratio (W / W ) between 1/15 and 1/2. The solvent is volatile, in particular, it serves as a drying promoter and is miscible with water and / or with solvent c).
Skønt dette ikke er foretrukket, kan præparatet til spot-on-administration eventuelt omfatte vand, især i et omfang som udgør 0 til 30% (volumen per volumen, vol/vol), især fra 0 til 5%.While not preferred, the spot-on administration composition may optionally comprise water, especially to an extent of 0 to 30% (v / v, v / v), in particular from 0 to 5%.
Præparatet til spot-on-administration kan også omfatte en antioxidant, som er bestemt til at inhibere oxidation med luft, idet dette middel især er til stede i et forhold fra 0,005 til 1% (vægt/vol) og fortrinsvis fra 0,01 til 0,05%.The spot-on administration composition may also comprise an antioxidant which is intended to inhibit oxidation with air, this agent being particularly present in a ratio of 0.005 to 1% (w / v) and preferably 0.01 to 0.05%.
Præparaterne ifølge opfindelsen, som er bestemt til selskabsdyr, især katte og hunde, administreres generelt ved at blive anbragt på huden ("spot-on"- eller "pour-on"-administration); dette er generelt en lokal administration inden for et overfladeområde på mindre end 10 cm2, især mellem 5 og 10 cm2, og specielt i to punkter og fortrinsvis lokaliseret mellem dyrets skuldre. Når præparatet først er anbragt, breder det sig især over hele dyrets krop og tørrer så uden at krystallisere eller modificere pelsens udseende (især ved fravær af en hvilken som helst hvidlig afsætning eller et støvet udseende) eller pelsens greb.The compositions of the invention, which are intended for pet animals, especially cats and dogs, are generally administered by application to the skin ("spot-on" or "pour-on" administration); this is generally a local administration within a surface area of less than 10 cm 2, especially between 5 and 10 cm 2, and especially at two points and preferably located between the shoulders of the animal. Once applied, it especially spreads throughout the animal's body and then dries without crystallizing or modifying the appearance of the coat (especially in the absence of any whitish deposit or dusty appearance) or the grip of the coat.
Præparaterne til spot-on-administration ifølge den foreliggende opfindelse er særligt fordelagtige som følge af deres virkning, deres virkningshastighed og det tiltalende udseende af dyrets pels efter administration og tørring.The spot-on administration compositions of the present invention are particularly advantageous because of their effect, rate of action, and the pleasing appearance of the animal's fur after administration and drying.
Som organisk opløsningsmiddel c) , der kan anvendes ifølge opfindelsen, kan nævnes: acetone, acetonitril, benzylalkohol, butyldiglycol, dimethyl-acetamid, dimethylformamid, dipropylenglycol-n-butylether, ethanol, isopropanol, methanol, ethylenglycol-monoethylether, ethylenglycol-monomethylether, monomethylacetamid, dipropy-lenglycol-monomethylether, flydende polyoxyethylenglycoler, propylenglycol, 2-pyrrolidon, især N-methylpyrrolidon, di-ethylenglycol-monoethylether, ethylenglycol og diethylphthalat eller en blanding af mindst to af disse opløsningsmidler.As organic solvent c) which can be used according to the invention can be mentioned: acetone, acetonitrile, benzyl alcohol, butyldiglycol, dimethylacetamide, dimethylformamide, dipropylene glycol-n-butyl ether, ethanol, isopropanol, methanol, ethylene glycol monoethyl ether, ethylene glycol monomethyl ether, , dipropylene glycol monomethyl ether, liquid polyoxyethylene glycols, propylene glycol, 2-pyrrolidone, especially N-methylpyrrolidone, diethylene glycol monoethyl ether, ethylene glycol and diethyl phthalate or a mixture of at least two of these solvents.
Som krystallisationsinhibitor b), der kan anvendes ifølge opfindelsen, kan der især nævnes: -polyvinylpyrrolidon, polyvinylalkoholer, copolymerer af vinylacetat og vinylpyrrolidon, polyethylenglycoler, benzylalkohol, mannitol, glycerol, sorbitol, polyoxyethy-lenerede sorbitanestere; lecithin, natriumcarboxymethyl-cellulose, acrylderivater såsom methacrylater og lignende, -anioniske tensider såsom alkalimetalstearater, især natrium-, kalium- eller ammoniumstearat; calciumstearat; triethanolaminstearat; natriumabietat; alkylsulfater, især natriumlaurylsulfat og natriumcetylsulfat; natrium-dodecylbenzensulfonat, natriumdioctylsulfosuccinat; fedtsyrer, især de der er afledt af kokosolie, -kationiske tensider såsom vandopløselige, kvaternære ammoniumsalte med formlen N+R'R' 'R' ' 'R' ' ' ',Y“, hvori grupperne R er eventuelt hydroxylerede carbonhydridgrupper, og Y~ er en anion af en stærk syre såsom halogenid-, sulfat-og sulfonatanioner; cetyltrimethylammoniumbromid er blandt de kationiske tensider, der kan anvendes, -aminsalte med formlen N+R'R''R''', hvori grupperne R er eventuelt hydroxylerede carbonhydridgrupper; octadecylamin-hydrochlorid er blandt de kationiske tensider, der kan anvendes, -ikke-ioniske tensider såsom eventuelt polyoxyethylenerede sorbitanestere, især polysorbat 80, polyoxyethylenerede alkylethere; polyethylenglycolstearat, polyoxyethylenerede derivater af ricinusolie, polyglycerolestere, polyoxyethylenerede fede alkoholer, polyoxyethylenerede fedtsyrer, copolymerer af ethylenoxid og propylenoxid, -amfotere tensider såsom substituerede laurylforbindelser af betain, eller fortrinsvis en blanding af mindst to af disse krystallisationsinhibitorer .As crystallization inhibitor b) which can be used according to the invention, in particular, mention may be made of: -polyvinylpyrrolidone, polyvinyl alcohols, copolymers of vinyl acetate and vinylpyrrolidone, polyethylene glycols, benzyl alcohol, mannitol, glycerol, sorbitol, polyoxyethylene sorbedol; lecithin, sodium carboxymethyl cellulose, acrylic derivatives such as methacrylates and the like, anionic surfactants such as alkali metal stearates, especially sodium, potassium or ammonium stearate; calcium stearate; triethanolamine; natriumabietat; alkyl sulfates, especially sodium lauryl sulfate and sodium cetyl sulfate; sodium dodecylbenzenesulfonate, sodium dioctylsulfosuccinate; fatty acids, especially those derived from coconut oil, cationic surfactants such as water-soluble quaternary ammonium salts of the formula N + R'R '' R '' 'R' '' ', Y', wherein the groups R are optionally hydroxylated hydrocarbon groups, and Y ~ is an anion of a strong acid such as halide, sulfate and sulfonate anions; cetyltrimethylammonium bromide is one of the cationic surfactants that can be used, amine salts of the formula N + R'R''R '', wherein the groups R are optionally hydroxylated hydrocarbon groups; octadecylamine hydrochloride is one of the cationic surfactants that can be used, nonionic surfactants such as optionally polyoxyethylenated sorbitan esters, especially polysorbate 80, polyoxyethylenated alkyl ethers; polyethylene glycol stearate, polyoxyethylenated derivatives of castor oil, polyglycerol esters, polyoxyethylenated fatty alcohols, polyoxyethylenated fatty acids, copolymers of ethylene oxide and propylene oxide, amphoteric surfactants such as substituted lauryl compounds of betaine, or preferably a mixture of at least two of
På særlig foretrukken måde vil et krystallisationsinhibitorpar, nemlig kombinationen af et filmdannelse middel af polymer type og et tensid, blive anvendt. Disse midler vil især blive udvalgt blandt forbindelserne nævnt som krystallisationsinhibitor b).In a particularly preferred way, a crystallization inhibitor pair, namely the combination of a polymer-type film-forming agent and a surfactant, will be used. In particular, these agents will be selected from the compounds mentioned as crystallization inhibitor b).
Blandt de filmdannende midler af polymer type, som er særligt fordelagtige, kan nævnes: -de forskellige polyvinylpyrrolidonkvaliteter, -polyvinylalkoholer, og -copolymerer af vinylacetat og vinylpyrrolidon.Among the polymeric film-forming agents which are particularly advantageous are the following: - the various polyvinylpyrrolidone grades, -polyvinyl alcohols, and copolymers of vinyl acetate and vinylpyrrolidone.
Hvad angår tensider foretrækkes især ikke-ioniske tensider og fortrinsvis polyoxyethylenerede sorbitanestere og især forskellige polysorbatkvaliteter, f.eks. polysorbat 80.In the case of surfactants, nonionic surfactants and preferably polyoxyethylenated sorbitan esters, and in particular various polysorbate grades, are particularly preferred. polysorbate 80.
Det filmdannende middel og tensidet kan inkorporeres i fortrinsvis ens eller identiske mængder inden for grænsen af den samlede mængde andet steds nævnte krystallisationsinhibitor.The film-forming agent and surfactant can be incorporated in preferably equal or identical amounts within the limit of the total amount of the other-mentioned crystallization inhibitor.
Det således frembragte par sikrer formålet med fravær af krystallisation på hårene og opretholdelse af det kosmetiske udseende af pelsen på en bemærkelsesværdig måde, dvs. uden nogen tendens til klæbrighed eller til et klæbrigt udseende, til trods for den høje koncentration af aktivt materiale.The pair thus produced ensures the purpose of the absence of crystallization on the hairs and the maintenance of the cosmetic appearance of the coat in a remarkable manner, ie. without any tendency to stickiness or to sticky appearance, despite the high concentration of active material.
Som coopløsningsmiddel d) kan der især nævnes absolut alkohol, isopropanol og methanol.As co-solvent d), in particular, absolute alcohol, isopropanol and methanol can be mentioned.
Som antioxidant anvendes især konventionelle midler så som: butylhydroxyanisol, butylhydroxytoluen, askorbinsyre, natriummetabisulfit, propylgallat og natriumthiosulfat eller en blanding af ikke mere end to af disse midler.In particular, as antioxidant, conventional agents such as: butyl hydroxyanisole, butyl hydroxytoluene, ascorbic acid, sodium metabisulfite, propyl gallate and sodium thiosulfate, or a mixture of not more than two of these agents are used.
Præparaterne til spot-on-administration ifølge opfindelsen fremstilles sædvanligvis ved simpel blanding af bestanddelene som tidligere angivet; fordelagtigt blandes til at begynde med det aktive materiale i hovedopløsningsmidlet, og de andre bestanddele eller adjuvanser tilsættes så.The spot-on administration compositions of the invention are usually prepared by simple mixing of the ingredients as previously indicated; advantageously mixed initially with the active material in the main solvent and the other ingredients or adjuvants then added.
Det administrerede volumen kan udgøre fra ca. 0,3 til 1 ml og fortrinsvis ca. 0,5 ml til katte, og fra ca. 0,3 til 3 ml til hunde i overensstemmelse med dyrets vægt.The volume administered may be from approx. 0.3 to 1 ml and preferably approx. 0.5 ml for cats, and from approx. 0.3 to 3 ml for dogs according to animal weight.
På en særligt foretrukken måde kan præparatet ifølge opfindelsen befinde sig i form af en koncentreret emulsion, suspension eller opløsning til spot-on-administration på et lille område af dyrets hud i almindelighed mellem de to skuldre (spot-on-type opløsning) . På en tydeligt mindre foretrukken måde kan der tilvejebringes former for opløsning eller suspension til forstøvning, opløsning, suspension eller emulsion til udhældning eller spredning på dyret (pour-on-type opløsning), olie, creme, salve eller en hvilken som helst anden flydende formulering til topisk administration.In a particularly preferred manner, the composition of the invention may be in the form of a concentrated emulsion, suspension or solution for spot-on administration on a small area of the animal's skin generally between the two shoulders (spot-on type solution). In a distinctly less preferred way, forms of solution or suspension may be provided for atomization, dissolution, suspension or emulsion for pouring or spreading on the animal (pour-on type solution), oil, cream, ointment or any other liquid formulation. for topical administration.
Fordelagtigt indeholder det brugsklare præparat en dosis fra 0,1 til 40 mg/kg af forbindelse (A) med formlen (I) og 0,1 til 40 mg/kg af forbindelse (B).Advantageously, the ready-to-use composition contains a dose of 0.1 to 40 mg / kg of compound (A) of formula (I) and 0.1 to 40 mg / kg of compound (B).
Fortrinsvis indeholder en brugsklar doseringsformulering især en til spot-on-administrering 1 til 20 mg/kg og især 2 til 10 mg/kg af forbindelse (A) , fibronil, og fra 1 til 30 mg/kg og fortrinsvis 2 til 10 mg/kg af en foretrukken forbindelse (B) eller 10 til 20 mg/kg af en anden forbindelse (B).Preferably, a ready-to-use dosage formulation contains, in particular, one for spot-on administration of 1 to 20 mg / kg and especially 2 to 10 mg / kg of compound (A), fibronil, and from 1 to 30 mg / kg and preferably 2 to 10 mg / kg. or 10 to 20 mg / kg of another compound (B).
Fordelagtigt kan der tilvejebringes brugsklare præparater til dosering til dyr med en vægt på henholdsvis 1-10, 10-20 og 20-4 0 kg.Advantageously, ready-to-use dosage preparations for animals weighing 1-10, 10-20 and 20-4 0 kg, respectively, can be provided.
I en anden udførelsesform, der er beregnet til tidsmæssigt opdelt administration, kan der fremstilles et præparat i form af et sæt som opdelt i samme pakning kombinerer et præparat indeholdende fipronil, og et præparat indeholdende forbindelse (B) , fortrinsvis pyriproxyfene, idet hvert af præparaterne indbefatter et vehikel, som tillader administrationen deraf på huden.In another embodiment intended for time-division administration, a composition in the form of a kit divided into the same package can be combined combining a composition containing fipronil and a composition containing compound (B), preferably the pyriproxyphenes, each of the compositions includes a vehicle which allows the administration thereof on the skin.
Fortrinsvis er hver af de to præparater beregnet til lokal spot-on-administration, og fortrinsvis er der beregnet en beholder indeholdende netop den krævede dosis til hver administration.Preferably, each of the two compositions is intended for local spot-on administration, and preferably a container containing just the required dose is provided for each administration.
Således kan et sæt i en pakke, f.eks. indeholde tre beholdere, der hver indeholder en enkelt dosis præparat med forbindelse (A) , og tre beholdere som hver indeholder en enkelt dosis præparat med forbindelse (B) , idet (A)-beholderne er adskilt fra (B)-beholderne ved mærker, former eller farver såvel som en bemærkning der specificerer, at (A)-beholderne og (B)- beholderne skal anvendes vekselvis med et interval f.eks. på én måned, idet der f.eks. begyndes med en (A)-beholder.Thus, a set in a package, e.g. contain three containers, each containing a single dose of compound (A), and three containers, each containing a single dose of compound (B), the (A) containers being separated from the (B) containers by labels, shapes or colors as well as a note specifying that (A) containers and (B) containers should be used alternately at an interval e.g. in one month, e.g. begin with an (A) container.
Præparaterne ifølge opfindelsen og især præparaterne til spot-on-administration har vist sig yderst effektive til den meget langvarige behandling mod blodmider på pattedyr og især små pattedyr såsom katte og hunde.The compositions of the invention, and in particular the compositions for spot-on administration, have proven to be extremely effective for the very long-term treatment of mammalian blood mites and especially small mammals such as cats and dogs.
Den opdagelse, at forbindelse (A) fipronil opløses i talg, således at hele dyret dækkes, og koncentreres i talgkirtlerne, hvorfra den gradvis frigives over et meget langt tidsrum, er en sandsynlig forklaring på denne langvarige virkning af disse præparater og vil måske også kunne forklare den langvarige virkning af den tilknyttede forbindelse (B) .The discovery that compound (A) fipronil is dissolved in sebum so that the entire animal is covered and concentrated in the sebaceous glands from which it is gradually released over a very long period of time is a likely explanation for this long-lasting effect of these preparations and may also be possible. explain the long-lasting effect of the associated compound (B).
De har også en vis virkning over for andre parasitiske insekter og især over for blodmider, og det vil være åbenbart, at administrationen af præparatet ifølge opfindelsen kan udstrækkes til en behandling for ectoparasitter eller endog endoparasitter, over for hvilke præparatet viser sig at have reel nytte, som praktisk er i stand til at blive opnået i overensstemmelse med kriterier inden for veterinærteknikken.They also have some effect on other parasitic insects and especially on blood mites, and it will be apparent that the administration of the composition of the invention can be extended to a treatment for ectoparasites or even endoparasites for which the preparation is found to be of real benefit. which is practically capable of being achieved in accordance with criteria in the veterinary field.
Hvor det er hensigtsmæssigt, kan præparatet ifølge opfindelsen også omfatte et andet insekticid og især imidaclopride.Where appropriate, the composition of the invention may also comprise another insecticide and in particular imidaclopride.
Andre fordele og karakteristika ved opfindelsen vil fremgå af eksemplerne, der er angivet i beskrivelsen nedenfor.Other advantages and features of the invention will become apparent from the examples set forth in the description below.
Præparatfremstillingseksemplet som følger omfatter som forbindelse (A) .The preparation example which follows comprises compound (A).
Til f.eks. at fremstille et præparat til lokal administrering til huden i overensstemmelse med opfindelsen kan følgende bestanddele fordelagtigt blandet sammen: al - forbindelse (B) i et forhold fra 1 til 20% (procent som vægt per volumen vægt/vol) a2 - forbindelse (A) i et forhold fra 5 til 15%, (procent som vægt per volumen vægt/vol).For example. to prepare a composition for topical administration to the skin in accordance with the invention, the following ingredients may advantageously be mixed together: a1 - compound (B) in a ratio of 1 to 20% (percent by weight per volume w / v) a2 - compound (A) in a ratio of 5 to 15%, (percent as weight per volume weight / vol).
Som eksempel omfatter præparaterne ifølge opfindelsen følgende koncentrationer (vægt/vol) af forbindelse (A) og (B) i et flydende medium omfattende en repræsentant for hver af bestanddelene b, c og d. Det samlede volumen er 1 ml.By way of example, the compositions of the invention comprise the following concentrations (w / v) of compounds (A) and (B) in a liquid medium comprising a representative of each of components b, c and d. The total volume is 1 ml.
Eksempel 1 fipronil 10% pyriproxyfene 5%Example 1 fipronil 10% pyriproxyphene 5%
Eksempel 2 fipronil 5% pyriproxyfene 5%Example 2 fipronil 5% pyriproxyphene 5%
Eksempel 3 fipronil 5% pyriproxyfene 20%Example 3 Fipronil 5% Pyriproxyphene 20%
Eksempel 4 fipronil 10% methoprene 30%Example 4 Fipronil 10% Methoprene 30%
Eksempel 5 fipronil 10% 1-(2,6-difluorbenzoyl)-3-(2-fluor-4-trifluormethyl)phenyl-urinstof 5%.Example 5 fipronil 10% 1- (2,6-difluorobenzoyl) -3- (2-fluoro-4-trifluoromethyl) phenylurea 5%.
Katte udsættes hver især for angreb med 100 lopper og udsættes atter for angreb hver 10. dag. Samtidig med den første manifestation modtager de en lokal administration på huden af 0,1 mg/kg af præparatet ifølge Eksempel 1. To måneder efter behandlingen og 10 dage efter den sidste udsættelse for angreb påvises ingen lopper, og de opsamlede æg viser sig at være ikke-levedygtige.Cats are each attacked with 100 fleas and re-attacked every 10 days. At the time of the first manifestation, they receive a topical administration to the skin of 0.1 mg / kg of the composition of Example 1. Two months after the treatment and 10 days after the last exposure to attack, no fleas are detected and the collected eggs appear to be non-viable.
Hunde behandlet i overensstemmelse med samme fremgangsmåde med præparater ifølge eksempel 1 og 2 udviser samme virkning af behandlingen 2 måneder efter administration af præparatet.Dogs treated according to the same procedure with compositions of Examples 1 and 2 exhibit the same effect of treatment 2 months after administration of the preparation.
Claims (31)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA201370137A DK178513B1 (en) | 2011-01-07 | 2013-03-11 | Insecticide combination preparation for use against mammalian blood mites, especially cats and dogs |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA201170008A DK177441B1 (en) | 1997-11-27 | 2011-01-07 | Composition for long-term protection against fleas in mammals, especially cats and dogs |
| DK201170008 | 2011-01-07 | ||
| DKPA201370137A DK178513B1 (en) | 2011-01-07 | 2013-03-11 | Insecticide combination preparation for use against mammalian blood mites, especially cats and dogs |
| DK201370137 | 2013-03-11 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DK201370137A DK201370137A (en) | 2013-03-11 |
| DK178513B1 true DK178513B1 (en) | 2016-04-25 |
Family
ID=48051910
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DKPA201370137A DK178513B1 (en) | 2011-01-07 | 2013-03-11 | Insecticide combination preparation for use against mammalian blood mites, especially cats and dogs |
Country Status (1)
| Country | Link |
|---|---|
| DK (1) | DK178513B1 (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0045424A1 (en) * | 1980-08-02 | 1982-02-10 | Bayer Ag | Pour-on formulations active against ticks |
| EP0295117A1 (en) * | 1987-06-12 | 1988-12-14 | Rhone-Poulenc Agriculture Limited | Derivatives of N-phenylpyrazoles |
| EP0500209A1 (en) * | 1991-01-18 | 1992-08-26 | Rhone-Poulenc Agrochimie | Pesticidal 1-(2-pyridyl)pyrazoles |
| FR2713889A1 (en) * | 1993-12-21 | 1995-06-23 | Sumitomo Chemical Co | Pesticidal compsn. contg. insect growth regulator and an N-aryl:di:azole |
-
2013
- 2013-03-11 DK DKPA201370137A patent/DK178513B1/en not_active IP Right Cessation
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0045424A1 (en) * | 1980-08-02 | 1982-02-10 | Bayer Ag | Pour-on formulations active against ticks |
| EP0295117A1 (en) * | 1987-06-12 | 1988-12-14 | Rhone-Poulenc Agriculture Limited | Derivatives of N-phenylpyrazoles |
| EP0500209A1 (en) * | 1991-01-18 | 1992-08-26 | Rhone-Poulenc Agrochimie | Pesticidal 1-(2-pyridyl)pyrazoles |
| FR2713889A1 (en) * | 1993-12-21 | 1995-06-23 | Sumitomo Chemical Co | Pesticidal compsn. contg. insect growth regulator and an N-aryl:di:azole |
Also Published As
| Publication number | Publication date |
|---|---|
| DK201370137A (en) | 2013-03-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK177397B1 (en) | Preparation for long-term protection against fleas in mammals, especially cats and dogs | |
| US6010710A (en) | Direct pour-on skin solution for antiparasitic use in cattle and sheep | |
| TWI494061B (en) | Local topical administration formulations containing indoxacarb | |
| CA2204745C (en) | Antiparasitic composition for the treatment and protection of pets | |
| RU2480197C2 (en) | Fipronil-containing compositions for external use by local application | |
| US6413542B1 (en) | Direct pour-on antiparasitic skin solution and methods for treating, preventing and controlling myasis | |
| DK177400B1 (en) | Solution of and use of 1- [2,6-C12-4-CF3-phenyl] -3-CN-4- [SO-CF3] -5-NH2-pyrazole to prepare the solution for direct application to the skin to eliminate parasites from cattle and sheep | |
| DK178513B1 (en) | Insecticide combination preparation for use against mammalian blood mites, especially cats and dogs | |
| DK177441B1 (en) | Composition for long-term protection against fleas in mammals, especially cats and dogs | |
| SE531435C2 (en) | Insecticide compound against fleas in mammals, especially dogs and cats | |
| AU2003257646B2 (en) | Direct pour-on skin solution for anitparasitic use in cattle and sheep | |
| AU763484B2 (en) | Direct pour-on skin solution for antiparasitic use in cattle and sheep | |
| AU5432901A (en) | Insecticidal combination effective against fleas on mammals, particularly cats and dogs | |
| AU2005201861A1 (en) | Insecticidal combination effective against fleas on mammals, particularly cats and dogs |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUP | Patent expired |
Expiry date: 20330311 |